Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2)

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2)

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 986 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Sponsor is also masked.
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study
Actual Study Start Date: December 4, 2015
Actual Primary Completion Date: March 29, 2017
Actual Study Completion Date: October 5, 2018

Arms:
- Experimental: Galcanezumab 120mg
- Experimental: Galcanezumab 240mg
- Placebo Comparator: Placebo
- Experimental: Galcanezumab 120mg Maximum Extended Enrollment Cohort
- Experimental: Galcanezumab 240mg Maximum Extended Enrollment Cohort
- Placebo Comparator: Placebo Maximum Extended Enrollment Cohort